Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 97 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.